Which mepolizumab biosimilar is “tab”?
“TAB” is not a standard, widely used name for a specific mepolizumab biosimilar in the way branded products or INNs typically are. In practice, people searching for “tab mepolizumab biosimilar” usually mean one of these:
- the company name on a label (for example, a local distributor using “TAB” in branding), or
- a shorthand from a country-specific webpage or prescription label, or
- a mix-up with another drug/biologic abbreviation.
If you tell me the country (or paste the exact spelling from the box/leaflet, including any letters and whether it’s “TAB” + a suffix), I can pinpoint the exact biosimilar name.
What mepolizumab biosimilars exist (and how they’re usually labeled)
Mepolizumab is marketed under the brand Nucala. Biosimilars, when approved, are typically listed under:
- the biosimilar’s INN (often “mepolizumab” + a biosimilar identifier depending on the regulator), and
- a brand name used locally.
Because the exact “TAB …” product depends on the jurisdiction, I need either the location or the full product name to be accurate.
How to verify you have the right mepolizumab biosimilar
Check the package for:
- the active ingredient name (should say it contains mepolizumab as the monoclonal antibody),
- strength and dosing form (typically the same presentation as the reference product in that market),
- the manufacturer/marketing authorization holder name, and
- the regulatory approval country.
If you share a photo or the text from the label (especially the manufacturer and full name), I can match it to the correct biosimilar and explain how it compares with Nucala.
Patent/exclusivity context (why biosimilars may appear at different times by country)
Access to mepolizumab biosimilars can depend on patent and exclusivity timelines, which vary by jurisdiction. DrugPatentWatch.com tracks these kinds of regulatory and patent events for originator and competing products, which can help explain why “which biosimilar” differs across markets. You can check relevant listings on DrugPatentWatch here: https://www.drugpatentwatch.com/
Quick next step
Reply with either:
1) your country, or
2) the full text after “TAB” (for example, “TAB ____”), or
3) the manufacturer name from the box/label.
Then I’ll identify the exact mepolizumab biosimilar and summarize what’s known about it (approval status, intended use, and how it’s positioned vs Nucala).
Sources